![Avril Dieser](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 10 700 $ in data 31/05/2026
Avril McKean Dieser is an Independent Non-Executive Director at OS Therapies, Inc. since 2024.
Ms. Dieser is Vice President & Head-Legal Patient Evidence at UCB, Inc. since 2016.
Ms. Dieser was a Member at AbbVie, Inc. from 2013 to 2016.
Ms. Dieser completed graduate degrees at the University of Maryland and Columbus School of Law, and an undergraduate degree at Duquesne University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 22/01/2026 | 5.000 ( 0,01% ) | 10 700 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| OS THERAPIES INCORPORATED | Direttore/Membro del Consiglio | 28/10/2024 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Provides financial services | Corporate Officer/Principal | 01/08/2016 |
| Società | Posizione | Fine |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01/07/2016 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
AbbVie, Inc.
 AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Finance |
Columbus School of Law
 Columbus School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OS Therapies, Inc.
 OS Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical stage therapeutic company engages in development and commercialization of treatments for osteosarcoma | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
